Evidence map›Paper›PMID 39136751›Full record

Observational studyJournal of neurology2024

Epidemiologic and clinical features of multisystem atrophy: a population-based study in Navarre, Spain.

M E Erro, P Arrondo, I Gastón, P Clavero, J Sánchez Ruiz de Gordoa, G Martí Andrés, R Valentí, J Delfrade, E Vicente

Abstract readObservational Study
In one paragraph

Observational study in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Multiple system atrophy related neurogenic bladder: mechanism and treatment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M E ErroDepartment of Neurology, Hospital Universitario de Navarra, C/Irunlarrea 3, 31008, Pamplona, Navarra, Spain. elena.erro.aguirre@cfnavarra.es.ORCID http://orcid.org/0000-0002-9707-4190
P ArrondoEpigenetic Group, NavarraBiomed, Pamplona, Spain.
I GastónDepartment of Neurology, Hospital Universitario de Navarra, C/Irunlarrea 3, 31008, Pamplona, Navarra, Spain.
P ClaveroDepartment of Neurology, Hospital Universitario de Navarra, C/Irunlarrea 3, 31008, Pamplona, Navarra, Spain.
J Sánchez Ruiz de GordoaDepartment of Neurology, Hospital Universitario de Navarra, C/Irunlarrea 3, 31008, Pamplona, Navarra, Spain.
G Martí AndrésDepartment of Neurology, Hospital Universitario de Navarra, C/Irunlarrea 3, 31008, Pamplona, Navarra, Spain.
R ValentíDepartment of Neurology, Clínica San Miguel, Pamplona, Spain.
J DelfradeNavarra Institute for Health Research (IdisNA), Pamplona, Spain.
E VicenteNavarra Institute for Health Research (IdisNA), Pamplona, Spain.

Funding

Departamento de Salud, Gobierno de Navarra Project 19-2021
6 · The paper itself

Abstract

backgroundEpidemiological studies on multisystem atrophy (MSA) are scarce. Our aim has been to analyse 10-year incidence, point prevalence, survival, and the time to diagnosis of MSA in Navarre, a northern Spanish region.

methodsThis is a population-based observational retrospective study, from 2012 to 2021, which covered the population of Navarre (followed until 31 December 2021). Data from various sources of health information were reviewed in order to identify all potential diagnoses of MSA, that were validated from medical records. Patients were included if they fulfilled the new Movement Disorder Society criteria.

resultsWe observed a crude average annual incidence rate (IR) of 0.49/100,000 person-years, with the highest occurring in the age group of 60-69 years. No significant IR differences by sex or subtype were observed. Point prevalence in December 2021 was 2.43/100,000 inhabitants. Joinpoint analysis for global incidence and prevalence experienced stable annual rates during the whole period, showing an upward trend for prevalence without a statistically significant slop. The median age at symptom onset was 65 years (range 47-76). The median time to diagnosis was 36 months, without statistically significant differences between sex, age at diagnosis or subtypes. Median time of survival from clinical onset was 7 years. Age of onset above 70 years and autonomic onset were associated with reduced survival.

conclusionsThis is the first population-based epidemiological study on MSA in Spain. It provides detailed incidence and prevalence data for MSA that may be useful for appropriate management of health resources.

Indexed as

Multiple System AtrophyAgedAged, 80 and overAge of OnsetFemaleHumansIncidenceMaleMiddle AgedPrevalenceRetrospective StudiesSpainAtypical ParkinsonismEpidemiologyIncidenceMultisystem atrophyPrevalenceSurvivalTime to diagnosis

Identifiers

PMID39136751
PMCPMC11446993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.